Theravance Q2 Loss Wider Than Expected, Revenues Rise YY
TBPH Stock | USD 9.42 0.18 1.95% |
Under 53% of Theravance Biopharma's investor base is interested to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are impartial at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.
Theravance |
Theravance misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Read at finance.yahoo.com
Theravance Biopharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Theravance Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Theravance Biopharma Fundamental Analysis
We analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Theravance Biopharma is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Theravance Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theravance Biopharma stock to make a market-neutral strategy. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with similar companies.
Peers
Theravance Biopharma Related Equities
TIL | Instil Bio | 16.79 | ||||
ASMB | Assembly Biosciences | 10.72 | ||||
CTMX | CytomX Therapeutics | 6.25 | ||||
CNTB | Connect Biopharma | 6.19 | ||||
SNSE | Sensei Biotherapeutics | 5.66 | ||||
NUVB | Nuvation Bio | 3.21 | ||||
OVID | Ovid Therapeutics | 1.83 | ||||
ACHL | Achilles Therapeutics | 0.94 | ||||
NXTC | NextCure | 2.50 |
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |